United States - English - NLM (National Library of Medicine)

carilion materials management - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx) - candesartan cilexetil 16 mg - candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (j

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - candesartan cilexetil, hydrochlorothiazide - tablets - 16/12.5 milligram - angiotensin ii antagonists and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil, quantity: 4 mg - tablet, uncoated - excipient ingredients: macrogol 8000; maize starch; hyprolose; magnesium stearate; carmellose calcium; lactose monohydrate; iron oxide red - treatment of hypertension.,treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction <=40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; macrogol 8000; hyprolose; carmellose calcium; magnesium stearate; maize starch; iron oxide red - treatment of hypertension.,treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction <=40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: macrogol 8000; lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose; maize starch; iron oxide red - treatment of hypertension.,treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction <=40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - candesartan cilexetil, quantity: 8 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose monohydrate; maize starch; carmellose calcium; macrogol 8000; magnesium stearate; iron oxide red - treatment of hypertension.,treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction <=40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.